We retrospectively carried out a descriptive and prognostic study of 76 human immunodeficiency virus-infected patients with cryptococcosis diagnosed by a positive culture of cerebrospinal fluid (CSF), blood, urine, or other body fluid or tissue. We focused on the 6S patients with cryptococcal meningitis. At diagnosis, the mean CD4 lymphocyte count was 46/mm 3 ; 86% of patients had fever; 67%, headache; 37%, stiff neck; 29%, altered mentation or confusion; 20% cranial nerve deficiency; and 48%, other focal deficiencies. Analysis of CSF specimens revealed the following results: normal (25% of the specimens), leukocyte count of <20/mm 3 (62%), positive India ink smear (87%), and positive cryptococcal antigen (92%). Twenty patients died within the first 3 months (3-month survival rate, 70%). A Cox regression model selected the following as prognostic parameters: age older than 30 years (relative risk [RR] = 2.1), CSF glucose level of <2 mmollL (RR = 3.7), previous admission to an intensive care unit (RR = 4.7), and mechanical ventilation (RR = 4.6). The outcome of cryptococcal meningitis in patients with AIDS remains difficult to predict at admission, and every case should be considered as potentially severe.
We retrospectively carried out a descriptive and prognostic study of 76 human immunodeficiency virus-infected patients with cryptococcosis diagnosed by a positive culture of cerebrospinal fluid (CSF), blood, urine, or other body fluid or tissue. We focused on the 6S patients with cryptococcal meningitis. At diagnosis, the mean CD4 lymphocyte count was 46/mm 3 ; 86% of patients had fever; 67%, headache; 37%, stiff neck; 29%, altered mentation or confusion; 20% cranial nerve deficiency; and 48%, other focal deficiencies. Analysis of CSF specimens revealed the following results: normal (25% of the specimens), leukocyte count of <20/mm 3 (62%), positive India ink smear (87%), and positive cryptococcal antigen (92%). Twenty patients died within the first 3 months (3-month survival rate, 70%). A Cox regression model selected the following as prognostic parameters: age older than 30 years (relative risk [RR] = 2.1), CSF glucose level of <2 mmollL (RR = 3.7), previous admission to an intensive care unit (RR = 4.7), and mechanical ventilation (RR = 4.6). The outcome of cryptococcal meningitis in patients with AIDS remains difficult to predict at admission, and every case should be considered as potentially severe.
Cryptococcus neoformans is a cosmopolitan fungus that produces human disease mainly in patients infected with HIV [1] but also in other immunocompromised patients, such as those with Hodgkin's disease and other lymphoreticular malignancies, those receiving corticosteroid therapy, or those with diabetes mellitus [2] . Cryptococcosis has been described in 30% of HIV-positive patients in Africa and Southeast Asia [3] but has occurred less often in industrialized countries (e.g., 6%-10% of HIV-infected patients in the United States have cryptococcosis) [4, 5] . In France, the epidemiology of cryptococcal infections is partially known: cryptococcosis occurs in only 2% of patients with AIDS (which is less than the rate in the United States), maybe because there is less tropical area [6] .
Cryptococcal infection is still a severe disease associated with high rates of early death and relapse. Despite antifungal treatment with in vitro efficacy, responses to treatment and reversion of negative culture results are slow [1] . Prognostic studies of early death due to cryptococcal disease have been carried out, but the results are conflicting [7] [8] [9] . Treatment of cryptococcosis, especially with meningeal involvement, remains in dispute and has not been standardized with regard to either antifungal therapy or management of intracranial hypertension [10] . Meningeal cryptococcosis seems to have a potential for causing rapid death or visual dysfunction, with blindness in some cases [11] [12] [13] . These rapidly progressive forms are not well known and have been the focus of few studies.
In this report, we describe the characteristics and clinical course of patients with AIDS and cryptococcosis and report data for a subset of patients characterized by a rapidly fatal outcome. We also attempt to disclose parameters that influence short-term outcome.
Materials and Methods

Patient Selection
We retrospectively reviewed the charts of HIV-positive patients with cryptococcal disease whose cases were managed between 1 January 1986 and 1 January 1994 in all four Infectious Disease Departments of the Bichat-Claude Bernard University Hospital (Paris); one of these departments is an intensive care unit (ICU).
Diagnosis of cryptococcal infection was based on a positive culture of CSF, blood, urine, or another body fluid or tissue specimen or demonstration of cryptococcal antigen in any body em 1996; 23 (August) fluid. CSF specimens were cultured on Sabouraud agar with chloramphenicol. Detection and measurement of cryptococcal antigen was done by means of latex agglutination kits; the Fumouze kit (Fumouze Diagnostics, Asnieres, France) was used until May 1993 (70 patients), and the somewhat more sensitive Pasteur kit (Sanofi-Pasteur, Mames la Coquette, France) was used thereafter (eight patients). Three patients in whom circulating cryptococcal antigen was found once were excluded from the study.
During the study period, 6,182 HIV-infected patients were treated in the hospital. From the computerized or noncomputerized files of patients cared for in each department and the mycology laboratory file, 99 HIV-infected patients with cryptococcosis were selected for the study. Complete records were available for 76 patients (all of whom were included in the study); for the remaining 23 patients, the initial clinical records or laboratory records were either incomplete (10 patients) or irretrievable (13 patients). At least two ELISAs and one western blot test revealed that all 76 study patients had antibodies to HIV.
Data Collection
For each of the 76 study patients, clinical information obtained within 48 hours after admission was abstracted from the medical and laboratory test records as well as from records of autopsy and biopsy findings. The following historical and clinical data were studied: sex, age, AIDS stage by the definition of the Centers for Disease Control and Prevention, Glasgow come scale score, simplified acute physiologic score, type and number of prior opportunistic infections, weight loss, antiretroviral and antifungal treatment, prior health status (normal daily activities, moderate restrictions, major restrictions, or confined to bed [14] ), fever, high-grade fever (temperature, ;:,39°C), headache, stiff neck, malaise, nausea, vomiting, confusion, seizures, evidence of brain stem compression, pupil status, altered mentation, neurological deficits (cranial nerves, cerebellar syndrome, and others), papilledema, cardiovascular collapse, skin lesions, and lung involvement.
Laboratory data included the CD4 lymphocyte count within the previous 3 months or at admission; leukocyte and platelet counts; serum levels of sodium, creatinine, and urea; liver enzyme levels; markers for cholestasis; CSF study results (glucose and protein levels, leukocyte count, lymphocyte count, India ink smear finding, cryptococcal antigen titer, and culture result); and positive extraneural specimens. Cerebral CT findings were also noted, as were antifungal drugs, treatment of cerebral edema, and use of mechanical ventilation. Finally, dates of relapses, culture negativity, and death were abstracted from medical charts.
Treatment
Antifungal therapy was chosen by the attending physicians and reflected their individual choices rather than an institutional protocol, except for seven patients who received amphotericin B in a lipid emulsion (Intralipid 20%; Pharmacia, Saint-Quentin en Yvelines, France). Eradication of the organism was defined as at least one negative culture of a specimen from a site that beforehand was positive.
Statistical Analysis
Prognostic analyses for patients with cryptococcal meningitis were carried out. The main endpoint for the prognostic analysis was overall survival (whatever the cause of death) within the first 3 months of the diagnosis of cryptococcosis, while time to ICU admission was defined as a secondary endpoint. Data on the time to treatment failure were estimated by the KaplanMeier method. For each endpoint, the univariate prognostic analysis was based on the logrank test, with continuous variables dichotomized according to the median value for the entire sample. Prior health status was rated on a severity scale as described above. All other variables (headache, fever, and other selected clinical symptoms and signs) were coded as dichotomous.
To summarize baseline prognostic information, variables found by the logrank test to be associated at the 10% level with the outcome were entered into a Cox regression model (a backward stepwise procedure selecting those variables providing additional predictive information to each other on the basis of the score test). The predictive value of several variables measured during the course of the disease was also tested by incorporation of these variables as time-dependent covariates into the Cox regression model. Levels of significance were represented by P values derived from two-sided tests. P values of :0::; .05 were considered statistically significant. Statistical analysis was performed with SAS and BMDP software packages (SAS Institute, Cary, NC; and BMDP, West Los Angeles; respectively).
Results
Of the 76 patients, 65 (86%) had meningeal or neurological involvement, and 11 (14%) had extraneural cryptococcosis. These two subgroups were studied separately. Isolated extraneural cryptococcosis was diagnosed for 11 patients. However, meningitis could not be completely ruled out in two of these patients for whom the diagnosis was confirmed immediately before or after death, respectively, without CSF cultures. The main characteristics of these 11 patients at diagnosis are reported in table 1.
There were three women. Seven patients were male homosexuals, 1 abused intravenous drugs, 1 acquired HIV infection during heterosexual activity, and 2 had no identifiable risk factors for HIV infection. The mean CD4 lymphocyte count was 40/mm 3 (range, 4-109/mm 3 ) . Nine patients already had AIDS before the onset of cryptococcosis. All 11 patients had blood dissemination of the organism: 10 had a positive test for serum cryptococcal antigen, and seven had one or more positive blood cultures. Cryptococci were recovered from lung tissue, sputum, or bronchoalveolar lavage fluid from 5 patients, a lymph node specimen from 1, and a liver specimen from 1. Ten patients were treated; nine received amphotericin B therapy, and three received fluconazole therapy. Treatment was successful for three patients. Eight of the 11 patients died, including four of extraneurological causes within the first 3 months of diagnosis. One patient died at ICU admission.
Of the 65 patients with meningitis, 62 were men and three were women (mean age, 33 years; range, 23-65 years) (table  1) . There were 7 black Africans, 1 Asian, and 57 Caucasians.
Risk factors for HIV infection were male homosexual contact in 33 patients, intravenous drug abuse in 10, and possibly contaminating heterosexual contact in 1I; no risk factors were identified for 11 patients. Cryptococcosis was the first manifestation of AIDS in 41 patients (62%). Thirteen patients (20%) had a history of Pneumocystis carinii pneumonia, and five (8°;;») had a history of infection with Toxoplasma gondii.
Of the 50 patients whose general health status was evaluated, 36 (72%) were in good general health (normal daily activities or moderate restrictions). The mean weight loss :± SD was 5 :± 5 kg (range, 0-25 kg). The mean time between onset of clinical symptoms and diagnostic confirmation :± SD was 15.5 :±3 days (range, 2~180 days). All patients had severe immunodeficiency; the mean CD4 lymphocyte count :± SD at diagnosis was 46 :± 52/mm" ( The typical manifestations of meningitis were absent in most patients, and nonspecific fever or headache was often the only clue to meningeal cryptococcosis (table 2) . Fever was the most frequent sign (86%); it was the only sign found in five patients. Headache was described in about two-thirds of patients, and stiff neck or a focal neurological deficit was described in more than one-third; less than one-fourth of the patients had nausea or vomiting. Altered consciousness was observed in 12 patients; cranial nerve palsies, in 11; cerebellar symptoms, in 4; and other focal deficits, in 10. Only three patients had seizures. Five of 44 assessed patients had papilledema. Cough, dyspnea, or abnormal pulmonary auscultatory sounds were descri bed in one-fifth of the patients. Five patients had cutaneous involvement related to cryptococcosis.
For 16 (26%) of the 62 evaluated patients, CSF parameters were normal ( two cases, and isolated cortical atrophy was found in three. Three patients had cryptococcal abscesses diagnosed by stereotaxic biopsy. Concomitant involvement of other organs was found in 93% of the 61 patients who underwent investigations for extraneural lesions. No organs were exempt. Diagnosis was based either on cultures of body fluids and tissue specimens or on detection of cryptococcal antigen. Blood cultures were positive in 37% of cases, and tests for serum cryptococcal antigen were positive in 93% (50 of 54). For four of 54 patients, the diagnosis of cryptococcal meningitis was not ruled out despite negative tests for serum cryptococcal antigen. Findings from the five autopsies and the premortem histologic studies demonstrated involvement of a wide range of organs, including lungs (12 patients), urinary tract (12), liver (4), skin (3), myocardium (2), lymph nodes (1), stomach (1), palate (1), pancreas (1), and both choroid and retina (1) .
During the induction period, 43 patients received therapy with amphotericin B (in a lipid emulsion in seven cases). The mean cumulative dose of amphotericin B was 1,039 mg (1,238 mg for long-term survivors and 671 mg for the other patients); 33 of the 43 patients received >0.7 mg/tkg : d). In 24 cases, amphotericin B therapy was given concomitantly with flucytosine therapy. Two patients received amphotericin B therapy Of the 65 patients with cryptococcal meningitis, 21 were admitted to the ICU, including 20 within the first 3 months. Of the 20 ICU admissions that occurred within the first 3 months, four were before and five were at the diagnosis of cryptococcosis, whereas the remaining 11 occurred 1-25 days after the diagnosis. The diagnosis of cryptococcal meningitis in seven patients was established after admission to the ICU. There were 17 men and three women (mean age, 37 years); the mean CD4 cell count was 54/mm 3 (range, 2-220/mm 3 ) . In 11 patients, cryptococcosis was the first AIDS-defining event. At diagnosis, 13 patients had fever; 16, headache; 12, stiff neck; 4, confusion; 2, seizures; 6, alterations in consciousness; 1, evidence of cerebral herniation; 4, cranial nerve palsies; 3, cerebellar manifestations; and 3, papilledema. Serum sodium levels were < 130 mEq/L in five of 16 assessed patients.
CSF studies of three of 20 patients at diagnosis were unremarkable. Of these 20 patients, 15 had CSF protein levels of >0.4 giL, 10 had CSF glucose levels of <2 mmol/L, and 7 had pleocytosis (> 20 cells/mrrr'), Microscopic examination of CSF sediment was consistently positive, cryptococcal antigen was detected in CSF from 12 of 13 patients, and cultures of CSF from 16 of 19 patients were positive. Fourteen patients underwent cerebral CT at diagnosis; the following results were found: normal findings (8) , cerebral atrophy (2), abscess (I), cerebral edema (1), and ventricular dilatation (2) . Most patients (15 of 16) had extraneural cryptococcosis, with the presence of the organism in the blood (13), liver (2), lungs (3) , urinary tract (4), and lymph nodes (1). Cryptococci were found at autopsy (2 patients), bronchoalveolar lavage (1), and hepatic biopsy (1) .
Five variables measured at hospital admission were selected by the logrank test as being associated at the 10% level with ICU admission, namely, delayed diagnosis. nuchal rigidity, era-.
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.05 P value" in an intraventricular tank. Forty-nine patients were given fluconazole therapy (daily dose, 400 mg). Tolerance of these drugs was satisfactory; for 16 patients, adverse effects required the discontinuation of treatment (renal failure due to amphotericin B, 9; cytopenia due to fluconazole, 5; liver dysfunction due to fluconazole, 2). Because some patients received sequentially different treatments, we analyzed survival according to the treatment received during at least the first 7 days. During the first week, 57% of the patients (37 of 65) were given fluconazole therapy, and 49% (32 of 65) were treated with amphotericin B with or without flucytosine.
Of the 65 patients with cryptococcal meningitis, 20 (31%) died within the 3 months after the diagnosis (figure 1) (estimated median survival time, 11.5 months). Cultures of specimens from only 34 patients (52%) became negative (mean interval, 37 days). Immunosuppressive therapy was given to patients who were still alive at 3 months; this therapy consisted of fluconazole (200 mg/d) for 39 patients, itraconazole for 1, and weekly amphotericin B for 2. Twelve patients relapsed up to 10 months after the diagnosis. Six patients had sequelae, including blindness, deafness, altered mentation, and motor deficits.
The univariate prognostic analysis of baseline data selected three variables that were associated at the 10% level with the outcome (table 2) : age, altered mentation, and CSF glucose level. When incorporated simultaneously into a multivariate Cox regression model, only the CSF glucose level remained informative (P = .009); patients with CSF glucose levels of <2 mmollL had a 3.3-fold increase in the risk of death (95% CI, 1.3-8).
We then studied the prognostic value of events that could occur during the course of cryptococcosis (i.e., lCU admission and mechanical ventilation), while adjusting for the three baseline parameters previously selected by the logrank test. Four of em 1996; 23 (August) nial nerve palsies, focal deficit, and altered mentation. Of these five variables, the presence of a focal deficit summarized predictive information; patients with a focal deficit had a 5.6-fold increase in the risk of ICU admission (95% CI, 2.0-15.6; P = .0003).
The mean Glasgow coma score at ICU admission was 9, and the mean simplified acute physiologic score was 17. Data on physical findings at ICU admission were available for 18 patients: 12 patients had fever or hypothermia; 8, headache; 9, stiff neck; 7, confusion; 5, seizures; 5, evidence of cerebral herniation; 6, nonreactive pupils; 5, anisocoria; 13, alterations in consciousness; 5, cranial nerve palsies; 1, cerebellar manifestations; 7, noncerebellar focal neurological deficits; 2, papilledema; and 4, evidence of shock. Seven patients underwent cerebral CT at ICU admission; the procedure showed normal findings (2), corticosubcortical atrophy (1), cerebral edema (2), and ventricular dilatation (2) . Fifteen patients received support with mechanical ventilation, usually because of neurological involvement. Twelve patients died within the first 3 months. Fifteen patients received treatment for cerebral edema (mannitol, 7; steroids, 6; or both 2).
Discussion
Cryptococcosis has been described as the first manifestation of AIDS in 21%-61 % of HIV-positive patients (62% in our series) and is usually responsible for meningitis [1, 4, 7, 9] . In our study, fever and headache were the most prevalent first symptoms; these findings are in agreement with other studies in which headache and fever were described as the first symptoms in 67%-100% and 62%-88% of patients, respectively [1, 4, 7, 9] . Therefore, cryptococcosis should be considered in all HIV-positive patients, particularly those with a mean CD4 cell count of <50/mm 3 , those with isolated fever or headache, and even in those without stiff neck (which is not usually observed [37% of our patients had stiff necksD, altered mentation (found in about one-fourth of our patients), and focal neurological deficits or seizures (which are even more rare) [4, 7, 9] .
Most patients with meningeal involvement had disseminated disease in our study (93% of patients) and in previous studies [4, 7, 9, 15, 16] . However, negative tests for serum cryptococcal antigen (7% in our study) do not eliminate the diagnosis, and a lumbar puncture should be done. Unfortunately, we did not record the opening CSF pressure, a parameter that has often been found to be elevated [4, 9] . Meningeal cryptococcosis should be considered even when CSF parameters are normal (26% of our patients) or when tests for CSF cryptococcal antigen are negative (8% of our patients).
Our data are consistent with previous studies showing the poor outcome of cryptococcal meningitis [2, 4, 8, 9, 15] . In a report of 111 HIV-negative patients, Diamond and Bennett [2] found a l-month mortality rate of 13%. Among HIV-infected patients, early estimates of mortality rates were 12% at week 2 [8] ,21% at week 6 [4] , and 29% overall during the "active period" [9] .
However, beside early deaths, complete resolution of clinical manifestations with conversion of negative culture results can be achieved, although slowly and inconsistently. Thus, predicting the outcome should help in decision making for patients with AIDS and cryptococcal meningitis. Therefore, we first performed a prognostic analysis to find baseline characteristics (i.e., those assessed at the diagnosis of cryptococcosis) that were associated with survival within the first 3 months. Apart from a low CSF glucose level, nonspecific prognostic factors, such as age and altered mentation, were first selected. Second, we performed a multivariate analysis that retained only a low CSF glucose level as being associated with an increased risk of death, as described previously for HIV-negative patients [2] .
To gather additional knowledge on predictive values, we investigated the potential influence of time to ICU admission, bearing in mind that one of the four infectious disease units of our hospital is an ICU. It has been reported that the outcome for HIV-positive patients admitted to an ICU because of respiratory assistance for neurological failure is very poor [17] . This poor outcome was similarly observed in our study, with both ICU admission and neurologically related mechanical ventilation identified as prognostic factors in addition to age and CSF glucose level. Otherwise, baseline predictive factors for ICU admission were different from those predictive for death, thus suggesting that besides differences in endpoints there are differences in the causes of death.
Contrary to the nonspecific factors predictive for death, ICU admission was associated with neurological manifestations such as stiff neck, altered mentation, cranial nerve palsies, and other focal deficits. Finally, as expected given the high level of redundancy between the five variables, the presence of focal neurological deficits summarized all the information at diagnosis that regarded the risk of subsequent ICU admission.
Many studies attempting to identify reliable prognostic factors available at diagnosis have been performed [2, 4, [7] [8] [9] 19] , but the results are conflicting. In a retrospective study of 111 cases of cryptococcal meningitis that was conducted before the AIDS epidemic, Diamond and Bennett [2] found that factors predictive of early death were positive India ink smears, an elevated opening CSF pressure, a low CSF glucose level, and a CSF cell count of <20/mm 3 • In 1986, Zuger et al. [9] reported that seven of 24 patients with active cryptococcosis died and found that factors of poor outcome were a CSF cryptococcal antigen titer of > 1:10,000 and relapse. In a retrospective study of 89 patients with meningitis, Chuck and Sande [4] observed 17 deaths during the first 6 weeks and reported that hyponatremia and positive cultures of extraneural specimens indicated a poor outcome.
In a univariate prognostic analysis of 68 patients [7] , abnormal results of cerebral CT and altered mentation were selected as factors of poor outcome. In a study of 41 patients with meningitis [19] , of whom 27 were HIV-infected and 14 had immunodeficiency due to other causes, a multivariate prognostic analysis revealed that HIV seropositivity and headache were associated with a poor outcome. In a prospective study by Saag et a1. [8] , in which the 2-week mortality rate was 12%, factors indicating a poor outcome were altered mental status, a titer of CSF cryptococcal antigen of > 1:1,024, and a CSF cell count of <20/mm 3 . The wide difference in isolated factors between the studies suggests that the course of meningeal cryptococcosis is difficult to predict, and this difficulty needs to be taken into account in the management of these patients' conditions. Indeed, although it has been suggested that treatment should be adapted to predicted outcome [1] , this adaptation is as yet unfeasible, and therapeutic improvements are needed to ameliorate the poor outcome for these patients. The standard treatment for HIV-negative patients with cryptococcal meningitis is amphotericin B with or without flucytosine [20] . However, a different strategy is used for patients with AIDS because of three main therapeutic concerns, namely, the reduction in the early mortality rate, clinical cure, and preservation of the quality of life. Currently, the most recommended therapy is high-dose amphotericin B (0. [23, 24] . Preliminary results showed that the combination of amphotericin B plus flucytosine is not better than amphotericin B alone and that fluconazole and itraconazole are similarly efficacious.
In our study, the response of the 32 patients who were initially treated with amphotericin B in combination with flucytosine was no better than the response of the 37 who were first treated with fluconazole. We did not specifically study immunosuppressive therapy because almost all our patients received fluconazole therapy at a daily dose of 200 mg, which is now well established as the standard treatment [18] . Nevertheless, it should be kept in mind that our study was not controlled; therefore, the assessment of treatment efficacy cannot be easily compared and interpreted. In our opinion, the high early mortality rate and the lack of reliable prognostic factors warrant the use of amphotericin B as first-line antifungal therapy for patients with AIDS and cryptococcal meningitis during the first 2 weeks.
The second component of the management of cryptococcal meningitis that will reduce the high mortality rate is the treatment of intracranial hypertension, which commonly occurs either after the diagnosis or in the course of the disease [25] . The cryptococcus itself or its secreted polysaccharides may impair CSF outflow through the arachnoid villi, although impaired CSF resorption due to diffuse arachnoiditis is more likely. Chuck and Sande [4] found elevated opening CSF pressures (>20 ern H 2 0 ) in 33 of 50 patients, while recovery or improvement has been reported after CSF derivation [25, 26] . Since intracranial pressure can be elevated in the absence of abnormal findings of cerebral CT, funduscopy and measurement of opening CSF pressure should be done routinely.
Interventions for lowering intracranial pressure, such as insertion of an intraventricular shunt or a lumbar drain or daily lumbar punctures (removing 25-30 mL of CSF/d), should be considered for patients with an elevated opening CSF pressure or severe papilledema, and acetazolamide therapy should be given to inhibit CSF production. A trial (ACTO 202) evaluating corticosteroid therapy as an adjunct to serial lumbar punctures for patients with high opening CSF pressures has been initiated [10] .
In conclusion, the prevalence of cryptococcosis in patients with AIDS in France seems low «2%). The short-term prognosis of this disease is poor; the risk of death within 3 months after the diagnosis is 30%, and the median survival after diagnosis is 11.5 months. At diagnosis, a few predictive factors, unrelated to HIV infection, have been shown. Improvement of the poor outcome would rely on the combination of effective antifungal therapy with an optimal diagnosis and early treatment of intracranial hypertension.
